Genmab A/S (Germany) Today
| GE9 Stock | EUR 274.90 0.50 0.18% |
PerformanceFair
| Odds Of DistressLow
|
Genmab A/S is trading at 274.90 as of the 1st of February 2026. This is a 0.18 percent down since the beginning of the trading day. The stock's lowest day price was 274.9. Genmab A/S has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat fair performance during the last 90 days. The performance scores are derived for the period starting the 3rd of November 2025 and ending today, the 1st of February 2026. Click here to learn more.
Genmab AS, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. Genmab AS was founded in 1999 and is based in Copenhagen, Denmark. GENMAB AS is traded on Frankfurt Stock Exchange in Germany. The company has 61.49 M outstanding shares. More on Genmab AS
Moving against Genmab Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genmab A/S Risk Profiles
Although Genmab A/S's alpha and beta are two of the key measurements used to evaluate Genmab A/S's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.52 | |||
| Semi Deviation | 1.77 | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.2 |
Genmab Stock Against Markets
Genmab Stock Analysis Notes
About 50.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Genmab AS, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. Genmab AS was founded in 1999 and is based in Copenhagen, Denmark. GENMAB AS is traded on Frankfurt Stock Exchange in Germany. To learn more about Genmab AS call the company at 45 70 20 27 28 or check out https://www.genmab.com.Genmab Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 21.8 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab A/S's market, we take the total number of its shares issued and multiply it by Genmab A/S's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Genmab Profitablity
Genmab A/S's profitability indicators refer to fundamental financial ratios that showcase Genmab A/S's ability to generate income relative to its revenue or operating costs. If, let's say, Genmab A/S is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Genmab A/S's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Genmab A/S's profitability requires more research than a typical breakdown of Genmab A/S's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38. Technical Drivers
As of the 1st of February, Genmab A/S retains the Downside Deviation of 2.09, market risk adjusted performance of 1.33, and Risk Adjusted Performance of 0.0525. Genmab A/S technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genmab A/S standard deviation, information ratio, treynor ratio, as well as the relationship between the variance and jensen alpha to decide if Genmab A/S is priced fairly, providing market reflects its last-minute price of 274.9 per share.Genmab A/S Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genmab A/S Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Genmab A/S price patterns.
Genmab A/S Outstanding Bonds
Genmab A/S issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genmab A/S uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genmab bonds can be classified according to their maturity, which is the date when Genmab AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Genmab A/S Predictive Daily Indicators
Genmab A/S intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genmab A/S stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 274.9 | |||
| Day Typical Price | 274.9 | |||
| Price Action Indicator | (0.25) | |||
| Period Momentum Indicator | (0.50) | |||
| Relative Strength Index | 51.39 |
Genmab A/S Forecast Models
Genmab A/S's time-series forecasting models are one of many Genmab A/S's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genmab A/S's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab A/S without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Genmab A/S Corporate Management
Elected by the shareholders, the Genmab A/S's board of directors comprises two types of representatives: Genmab A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab A/S's management team and ensure that shareholders' interests are well served. Genmab A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Mancini | Ex COO | Profile | |
| Judith MD | Exec Officer | Profile | |
| Birgitte MSc | Ex Officer | Profile | |
| Anthony Pagano | Ex CFO | Profile | |
| Peter Ros | Sr Accounting | Profile | |
| Andrew Carlsen | VP Director | Profile | |
| Jan Winkel | Pres CoFounder | Profile |
Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.